🍄 Josh Bartch is the CEO of Mydecine Innovations Group, a psychedelics company that is researching naturally sourced psychedelic therapeutics targeting PTSD and smoking cessation.  In this episode of The Integration Conversation, Josh joins us for a full hour and tells us about Mydecine's clinical trials, its research on functional mushrooms, and makes his pitch for why Mydecine is undervalued relative to its peers.    Questions we answer:  Is Mydecine Undervalued?  What lessons from the cannabis boom can we apply to the shroom boom?   Is natural psilocybin better than synthetic psilocybin?   What is the entourage effect?  🔥 Invest in Psychedelic Startups with Us 🔥 go to https://theintegration.co and click on "invest in psychedelic startups"  The Integration Conversation is a podcast that covers the emerging psychedelics industry from a business perspective, and aims to be your number 1 resource for investing in psychedelics,  psychedelic investing and psychedelic business.  ⛓ All our links:  https://theintegration.co 📝 My notes on psychedelic investing:  https://brompersonal.s3-us-west-2.amazonaws.com/assets/broms-notes-psychedelic-investing.pdf   🎧 Listen on Spotify and other podcast platforms:  https://anchor.fm/theintegrationco 🐦 brom on twitter:  https://twitter.com/therealbrom 🎇 Clips and other stuff on Instagram:  https://instagram.com/theintegrationco  ⏰ Timestamps:  Disclaimer: This video is not financial advice. Brom holds shares in Mydecine and other psychedelic stocks.